Startseite Kongressberichte & Archiv ASCO20 Virtual Scientific Meeting Oral Sessions CNS Tumours

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

2500 Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C.

Kazuhiko Mishima, Ryo Nishikawa, Yoshitaka Narita, et al.
 
The abstract concludes: 
This study failed to demonstrate the benefit of the addition of TMZ to WBRT and adjuvant TMZ in newly diagnosed PCNSL. Possible biomarkers including methylation status of the MGMT promoter in the tumors will be analyzed. Clinical trial information: jRCTs031180207.

--------------------------------------------------------------------------------------------------------------------------------------------------------

2501 Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).
 
Antonio Marcilio Padula Omuro, Lisa Marie DeAngelis, Theodore Karrison, et al. 
 
The abstract concludes: 
The study met the primary endpoint, demonstrating the addition of LD-WBRT to R-MPV-A improves PFS in newly diagnosed PCNSL. As per investigator’s assessment, NT rates were not statistically significantly increased, but further neuropsychological testing and neuroimaging analyses are ongoing to characterize cognitive decline and how it compares to other consolidation treatments. Clinical trial information: NCT01399372.

--------------------------------------------------------------------------------------------------------------------------------------------------------

2502 Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.
 
Priscilla Kaliopi Brastianos, Erin Twohy, Elizabeth Robins Gerstner, et al.
 
The abstract concludes: 
GSK2256098 had excellent tolerability andresulted in an improved PFS6 rate in pts with recurrent or progressive NF2-mutated meningiomas. Trial endpoint was met. FAK inhibition warrants further evaluation in this patient population. Support: U10CA180821, U10CA180882; https://acknowledgments.alliancefound.org Clinical trial information: NCT02523014.

-----------------------------------------------------------------------------------------------------------------------------------------------------

2503 The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pool analysis of cooperative group clinical trials.

Adriana Fonseca, Cecile Faure-Conter, Matthew Murray, Jet al. 

The abstract concludes: 
Herein, we have assembled the largest prospective cohort to date of relapsed intracranial germ cell tumors. TM are highly sensitive detecting relapse/progression in CNS-NGGCT patients with elevated TM at diagnosis. The routine use of TM for relapse surveillance in patients with CNS-NGGCT can decrease the frequency of cross-sectional imaging, therefore, reducing lengthy hospital visits, sedation procedures and decreasing health-care costs.

--------------------------------------------------------------------------------------------------------------------------------------------------------

2504 Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.
 
Ingo K. Mellinghoff, Katherine B. Peters, Timothy Francis Cloughesy, et al.
 
The abstract concludes: 
In this previously treated population with non-enhancing glioma, VOR was associated with a favorable safety profile. The study results also show encouraging preliminary activity within that population, with PFS duration extending to 24 months or longer in 60% of participants. A global randomized phase 3 study of VOR in grade 2 non-enhancing glioma pts who have had surgery only is currently enrolling (NCT04164901). Clinical trial information: NCT02481154.

--------------------------------------------------------------------------------------------------------------------------------------------------------

2505  A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.
 
Macarena Ines De La Fuente, Howard Colman, Mark Rosenthal, et al.
 
The abstract concludes: 
SA olutasidenib at 150 mg BID demonstrates acceptable safety and tolerability with preliminary clinical activity in glioma pts. Evaluation of CO is ongoing. Updated safety and clinical activity, as well as evaluations of serum/CSF PK/PD will be provided. Clinical trial information: NCT03684811.

--------------------------------------------------------------------------------------------------------------------------------------------------------

2506 Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade IDH-mutant diffuse gliomas.
 
Nancy Ann Oberheim Bush, Yao Yu, Javier Villanueva-Meyer, et al.
 
The abstract concludes: 
TMZ-induced hypermutation is associated with high grade transformation, unique patterns of dissemination and shortened survival after transformation. Next generation sequencing should be considered in this patient population. These data have important implications for the management of newly diagnosed and recurrent IDH-mutant low grade gliomas.

--------------------------------------------------------------------------------------------------------------------------------------------------------